FDA picks Nephrodite’s implantable dialysis system for TAP pilot (opens in new tab)

Nephrodite is joining the FDA Total Product Life Cycle Advisory Program (TAP) pilot for its Holly implantable continuous dialysis system, which won FDA Breakthrough Device Designation last year. The medical device startup’s latest regulatory win puts it in a relatively small club. The FDA designed the TAP pilot to expedite patient access to innovative medical… The post appeared first on .